Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 0
---
As filed with the U.S. Securities and Exchange Commission on October17, 2025. Registration No. 333 -284075 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 _____________________________________ POST -EFFECTIVEAMENDMENT NO. 1 TO FORM F -4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933 _____________________________________ NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) _____________________________________

| Switzerland                     |     |                         3841 |     | Not Applicable        |
| (State or other jurisdiction of 
 incorporation or organization)  |     | -Primary standard industrial 
   classification code number |     | -I.R.S. Employer      
 Identification Number |

The Circle 6
8058 Zurich, Switzerland
Tel: +41.44.512.2150 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) _____________________________________ Puglisi & Associates
850 Library Avenue, Suite 204
Newark, DE 19711
Tel: 302-738-6680 (Name, address, including zip code, and telephone number, including area code, of agent for service) _____________________________________ Copies to:

| Oded Har-Even, Esq.         
 Howard E. Berkenblit, Esq.  
 Ron Ben-Bassat, Esq.        
 Sullivan & Worcester LLP    
 1251 Avenue of the Americas 
 New York, NY 10020          
 Tel: (212) 660-3000         |     | Dr. Matthias Courvoisier      
 Baker McKenzie Switzerland AG 
 Holbeinstrasse 30             
 Zurich, Switzerland 8034      
 Tel: +41 44 384 14 14         |     | Oded Kadosh, Esq.                   
 Max Lindenfeld, Esq.                
 Pearl Cohen Zedek Latzer Baratz LLP 
 7 Times Square, 19th Floor          
 New York, New York 10036            
 Tel: (646) 878-0800                 |

_____________________________________ Approximate date of commencement of proposed sale of the securities to the public: As soon as practicable after this Registration Statement becomes effective and all other conditions to the proposed merger of NLS Pharmaceutics (Israel) Ltd., a wholly owned subsidiary of NLS Pharmaceutics Ltd., with and into Kadimastem Ltd. described in the enclosed proxy